Current Report Filing (8-k)
March 18 2020 - 11:33AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 12, 2020
OWC
Pharmaceutical Research Corp.
(Exact
Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State
of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
2
Ben Gurion Street, Ramat Gan, Israel
|
|
4514760
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, including area code: 972 (0) 3-758-2657
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
None
|
|
None
|
|
None
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
(a)
|
On
March 12, 2020, Stanley Hirsch resigned as Chairman and Director of both OWC Pharmaceutical Research Corp. (the “Company”)
and its wholly-owned Israeli subsidiary, One World Cannabis Ltd (“One World Cannabis”) and as a member of the
Company’s Audit Committee.
|
|
|
(b)
|
On
March 12, 2020, the Company’s Board of Directors appointed Mr. Amir Ohad to the Board of Directors.
|
Amir
Ohad, age 57, has served as the Chairman of OHK Medical Devices, Inc., a company which manufactures and sells innovative orthopedic
and vascular surgery products, since 2015. Mr. Ohad also serves as a director of Massivit 3D Printing Technologies Ltd. and iSonea
(Israel) Ltd. Mr. Ohad has served as an associate in the International Institute for Counter-Terrorism at the Interdisciplinary
Academic Institution in Hertzeliya, Israel since 2017. Mr. Ohad served more than 25 years of as a senior executive in private
and public companies. From 2005 to 2007, Mr. Ohad served as the chief executive officer of Alqemia Group (Kafrit Industries),
a publicly traded specialty compounding firm and served as the chief financial officer of ScitexVision (acquired by Hewlett Packard
in 2005) from 2000 to 2005.
Mr.
Ohad received his Masters of Business Administration and Masters of Arts from The Hebrew University of Jerusalem.
(c)
|
On
March 13, 2020, the Company appointed Mr. Amir Ohad as Chairman of the Company and One World Cannabis. Mr. Ohad will receive
a base salary of $7,500 per month for a minimum period of six (6) months.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
OWC
PHARMACEUTICAL RESEARCH CORP.
|
|
|
|
|
By:
|
/s/
Zvi Riterband
|
|
Name:
|
Zvi Riterband
|
|
Title:
|
Chief Executive Officer
|
Dated:
March 18, 2020
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Sep 2024 to Oct 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Oct 2023 to Oct 2024